Inventiva’s fibrosis flop hits Nash hopes
Intercept Pharma is One Step Closer to Filing for Approval of First NASH Treatment
Gilead’s Pivot to NASH Hits a Snag as Its Drug Flunks Phase III Trial
The 2019 pipeline report: Changing the treatment paradigm
A Talk With Robert Jacks, New CEO of NASH and Fibrotic Drugmaker Indalo
Is the Smoldering NASH Market Ready to Burst Into Flames?
The 20 Hottest Pipeline Drugs to Watch in 2019
Συμμαχίες γιγάντων για νέα φάρμακα κατά της ηπατικής νόσου (NASH)
NASH drugs come into focus as field awaits late-stage data
Pfizer and Novartis Ink Deal to Test Combination Therapies for NASH
Although the overall stock market has been a bit jittery as the result of a trade war, biotech stocks have been surprisingly steady—at least in comparison to their usual … Continue Reading 3 Biotech Stocks That Might Double Your Money in the Short Term
2018 is already half over, but expect fireworks now that President Trump has turned his attention to seeking lower drug prices. The Tweeter-in-Chief publicly shamed companies that have tried to … Continue Reading 7 companies to watch during Q2 earnings
Investors love their takeover rumors, and with biopharma having a good year for mergers and acquisitions, there’s been plenty to keep them busy. Here’s two takeover rumors that came out of … Continue Reading Rumor Alert: Merck KGaA to Buy Madrigal and Roche to Acquire Tesaro?
There are dollar signs in the treatment of nonalcoholic steatohepatitis (NASH). The market is pegged to hit $25 billion by 2026 and companies are flooding the developmental pipeline with potential … Continue Reading NASH Pipelines Face Questions as Drugs Near Potential Approval
Since 2014, investment in Non-Alcoholic SteatoHepatitis (NASH) has taken off with a fervor reminiscent of immuno-oncology. What’s it all about? Jean-Christophe Marcoux “NASH is a well-recognized health emergency,” says Jean-Christophe … Continue Reading Not to be Underestimated: What’s the Hype around NASH?